RESUMEN
Salt iodisation is considered a key public health measure for assuring adequate iodine intake in iodine-deficient countries. In Slovenia, the iodisation of all salt was made mandatory in 1953. A considerable regulatory change came in 2003 with the mandatory iodisation of rock and evaporated salt only. In addition, joining the European Union's free single market in 2004 enabled the import of non-iodised salt. The objective of this study was to investigate the extent of salt iodising in the food supply. We examined both the availability and sale of (non-)iodised salt. Average sales-weighted iodine levels in salt were calculated using the results of a national monitoring of salt quality. Data on the availability and sales of salts were collected in major food retailers in 2014. Iodised salt represented 59.2% of the salt samples, and 95.9% of salt sales, with an average (sales-weighted) level of 24.2 mg KI/kg of salt. The average sales-weighted KI level in non-iodised salts was 3.5 mg KI/kg. We may conclude that the sales-weighted average iodine levels in iodised salt are in line with the regulatory requirements. However, the regulatory changes and the EU single market have considerably affected the availability of non-iodised salt. While sales of non-iodised salt are still low, non-iodised salt represented 33.7% of the salts in our sample. This indicates the existence of a niche market which could pose a risk of inadequate iodine intake in those who deliberately decide to consume non-iodised salt only. Policymakers need to provide efficient salt iodisation intervention to assure sufficient iodine supply in the future. The reported sales-weighting approach enables cost-efficient monitoring of the iodisation of salt in the food supply.
Asunto(s)
Enfermedades Carenciales/prevención & control , Abastecimiento de Alimentos , Yodo/deficiencia , Política Nutricional , Cloruro de Sodio Dietético/efectos adversos , Bases de Datos Factuales , Enfermedades Carenciales/epidemiología , Enfermedades Carenciales/etiología , Enfermedades Carenciales/fisiopatología , Unión Europea , Etiquetado de Alimentos , Abastecimiento de Alimentos/economía , Bocio Endémico/epidemiología , Bocio Endémico/etiología , Bocio Endémico/prevención & control , Promoción de la Salud , Humanos , Yodo/análisis , Yodo/química , Yodo/economía , Yodo/uso terapéutico , Cooperación del Paciente , Yoduro de Potasio/análisis , Yoduro de Potasio/economía , Yoduro de Potasio/uso terapéutico , Eslovenia/epidemiología , Cloruro de Sodio Dietético/análisis , Cloruro de Sodio Dietético/economía , Cloruro de Sodio Dietético/uso terapéuticoRESUMEN
BACKGROUND: In 2009, the Michigan Department of Community Health (MDCH) made potassium iodide (KI), a nonprescription radio-protective drug, available by mailing vouchers redeemable at local pharmacies for KI tablets, at no cost to residents living within 10 miles of Michigan's 3 nuclear power plants (NPPs). MDCH conducted an evaluation of this program to determine Michigan's KI coverage and to assess general emergency preparedness among residents living near the NPPs. METHODS: KI coverage was estimated based on redeemed voucher counts and the 2010 Census. Telephone surveys were administered to a random sample (N = 153) of residents living near Michigan's NPPs to evaluate general emergency preparedness, reasons for voucher use or nonuse, and KI knowledge. RESULTS: Only 5.3% of eligible residences redeemed KI vouchers. Most surveyed residents (76.5%) were aware of living near an NPP, yet 42.5% reported doing "nothing" to plan for an emergency. Almost half of surveyed voucher users did not know when to take KI or which body part KI protects. Among voucher nonusers, 48.0% were either unaware of the program or did not remember receiving a voucher. CONCLUSIONS: Additional efforts are needed to ensure that all residents are aware of the availability of KI and that recipients of the drug understand when and why it should be taken. Minimal emergency planning among residents living near Michigan's NPPs emphasizes the need for increased emergency preparedness and awareness. Findings are particularly salient given the March 2011 Fukushima Daiichi Nuclear Power Plant emergency in Japan.
Asunto(s)
Planificación en Desastres , Medicamentos sin Prescripción/provisión & distribución , Plantas de Energía Nuclear , Yoduro de Potasio/provisión & distribución , Traumatismos por Radiación/prevención & control , Adulto , Anciano , Anciano de 80 o más Años , Desastres , Femenino , Financiación Gubernamental/métodos , Humanos , Masculino , Michigan , Persona de Mediana Edad , Yoduro de Potasio/economía , Investigación Cualitativa , Liberación de Radiactividad Peligrosa , Neoplasias de la Tiroides/etiología , Neoplasias de la Tiroides/prevención & controlRESUMEN
Sporotrichosis is the most common subcutaneous mycosis. It is usually acquired by traumatic inoculation, and it is caused by one of the species of the Sporothrix schenckii complex. More than 6 species, such as S schenckii sensu stricto, Sporothrix brasiliensis, Sporothrix globosa, Sporothrix mexicana, and Sporothrix albicans, have been identified by molecular techniques. The most common presentation is cutaneous disease, which is classified into fixed and lymphocutaneous forms. Osteoarticular, pulmonary, mucosal, disseminated, and systemic infections are less common and usually occur in immunosuppressed individuals. The diagnosis is suggested by biopsy specimen and confirmed by tissue culture. Itraconazole is considered the treatment of choice, although in some undeveloped countries potassium iodide is still used, owing to its safety and low cost. For systemic or disseminated cases, amphotericin B is the treatment of choice.
Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Itraconazol/uso terapéutico , Yoduro de Potasio/uso terapéutico , Esporotricosis/tratamiento farmacológico , Anfotericina B/economía , Animales , Antifúngicos/economía , Análisis Costo-Beneficio , Vectores de Enfermedades , Humanos , Itraconazol/economía , Yoduro de Potasio/economía , Sporothrix/aislamiento & purificación , Esporotricosis/patología , Esporotricosis/transmisiónAsunto(s)
Cromoblastomicosis/tratamiento farmacológico , Yoduro de Potasio/uso terapéutico , Anciano , Antifúngicos/economía , Antifúngicos/uso terapéutico , Cromoblastomicosis/patología , Análisis Costo-Beneficio , Humanos , Masculino , Naftalenos/economía , Naftalenos/uso terapéutico , Yoduro de Potasio/efectos adversos , Yoduro de Potasio/economía , TerbinafinaRESUMEN
Potassium Iodide is the antimycotic of choice for the treatment of cutaneous sporotrichosis, because of its efficacy, safety and low cost. We carried out a review of published studies on the benefits and adverse reactions of using SSKI (Saturated Solution Potassium Iodide) as treatment for sporotrichosis, but could not identify any well-designed clinical trails. There is an urgent need to conduct randomized double-blind placebo-controlled trials and critically assess usefulness of SSKI by using a standardize monitoring or an effective self-report system.